|
The experience of using genetically engineered biological drugs in children with various forms of JIA in the Karaganda region
|
|
| Author:
|
SINM.A , ZHUPENOVA D.E, KENZHETAYEVA T.A, ILYASSOVA G.T, SHAIKINA S.N, TUREKHANOVA A.A, NURGALIEVAVA E.F
|
| Abstract:
|
The article presents the experience of the use of biological drugs for the treatment of children with juvenile idiopathic arthritis in the cardiac rheumatology department of the KGH "Karaganda Children's Hospital" for the period from 01/01/2013 till 31/12/2017. In recent years, significant progress has been made in the treatment of juvenile chronic arthritis through the use of genetically engineered biological products.
The study included 46 patients with JIA who were on genetic engineering biological therapy (girls 28-60.8%, boys 18-39.1%). Among all patients, 12 (26.1%) suffered from the oligoarticular variant of juvenile idiopathic arthritis with (JIA), 15 (32.6%) from the polyarticular seronegative variant (JIA), 14 (30.4%), and the systemic form (JIA); other variants 5 (10.9%). Adalimumab was used in 24 patients (50.2%). Tocilizumab in 17 (30%), 14 of them had a systemic version of JIA. Infliximab in 5 patients (10.8%).
|
| Keyword:
|
juvenile idiopathic arthritis, genetically engineered biologicals, anti-TNF drugs, anti-interleukin-6 drugs.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP1.296
|
| Download:
|
Request For Article
|
|
|